Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is a biopharmaceutical company with a promising pipeline of gene therapies and a COVID-19 vaccine. They have received positive results for their Phase 2 study of OCU410 for geographic atrophy and have plans to conduct a pivotal trial for medium dose administration. They have also raised significant funding and have multiple potential products with orphan drug designations, including OCU410ST for Stargardt disease. However, there is a potential risk of legal expenses for intellectual property protection. Overall, Ocugen is a promising company in the biotech industry with a focus on innovative treatments for rare diseases.

Bears say

Ocugen is a development-stage company with a strong focus on gene and cell therapies for retinal diseases. However, despite promising preliminary data, there are significant risks to the achievement of their target price. These risks include the need for future financing, competition from major pharmaceutical companies with greater resources and experience, and potential regulatory hurdles. Additionally, the slow progression of the diseases they are targeting may make it difficult to reliably measure the effectiveness of their therapies.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.